Treatment of refractory Hodgkin's lymphoma patients with an anti-CD25 ricin A-chain immunotoxin (original) (raw)
References
De Vita VT, Molloy Hubbard S . Hodgkin's lymphoma New Engl J Med 1983 328: 560–565 Google Scholar
Longo IL, Young RC, Wesley M . Twenty years of MOPP therapy for Hodgkin's lymphoma J Clin Oncol 1986 4: 1295–1306 ArticleCASPubMed Google Scholar
Riethmüller G, Schneider-Gaedicke E, Schlimok G, Schmiegel W, Raab R, Hoeffken K, Gruber R, Pichlmaier H, Hirche H, Pichlmayr R, Buggisch P, Witte R and the German Cancer Aid . 17-1A Study Group. Randomized trial of monoclonal antibody for adjuvant therapy of resected Dukes'C colorectal carcinoma Lancet 1994 343: 1177–1183 ArticlePubMed Google Scholar
Ro DC, Griffin JD, Belvin M, Blaettler WA, Lambert JM, Ritz J . Anti-My9-blocked ricin: an immunotoxin for selective targeting of acute myeloid leukemia cells Blood 1991 77: 2404–2412 Google Scholar
Gribben JG, Freedman AS, Neuberg D, Roy DC, Blake KW, Woo SD, Grossbard ML, Rabinowe SN, Coral F, Freeman GJ, Ritz J, Nadler LM . Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma New Engl J Med 1991 325: 1525–1533 ArticleCASPubMed Google Scholar
Kanzler H, Hansmann M-L, Kapp U, Wolf J, Diehl V, Rajewsky K, Kueppers R . Molecular single cell analysis demonstrates the derivation of a peripheral blood derived cell line (L1236) from the Hodgkin/Reed–Sternberg cells of a Hodgkin's lymphoma patient Blood 1996 87: 3429–3436 CASPubMed Google Scholar
Wolf J, Kapp U, Bohlen H, Kornacker M, Schoch C, Stahl B, Muecke S, von Kalle C, Fonatsch C, Schaefer HE, Hansmann M-L, Diehl V . Peripheral blood mononuclear cells of a patient with advanced Hodgkin's lymphoma give rise to permanently growing Hodgkin/Reed–Sternberg cells Blood 1996 87: 3418–3428 CASPubMed Google Scholar
Simonsson B . Treatment of minimal residual disease in acute myelogenous leukemia (AML): focus on immunotherapeutic options Leukemia 1996 10: (Suppl. 2) 44–52 Google Scholar
Grossbard ML, Gribben JG, Freedman AS, Lambert J, Kinsella J, Rabinowe S, Eliseo L, Taylor J, Blatter W, Epstein C, Nadler L . Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin's lymphoma Blood 1993 81: 2263–2271 CASPubMed Google Scholar
Schnell R, Barth S, Diehl V, Engert A . Hodgkin's disease. Future treatment strategies: fact or fiction. In Diehl V (ed). Bailliéres Clinical Haematology Bailliére Tindall: London 1996 pp 573–593 Google Scholar
Hsu SM, Jaffe ES . Leu M1 and peanut agglutinin stain the neoplastic cells of Hodgkin's lymphoma Am J Clin Pathol 1984 82: 29–32 ArticleCASPubMed Google Scholar
Hsu SM, Ho YS, Hsu PL . Effect of monoclonal antibodies anti-2H9, anti-IRac, and anti-HeFi-1 on the surface antigens of Reed–Sternberg cells J Natl Cancer Inst 1987 79: 1091–1097 CASPubMed Google Scholar
Stein H, Mason DY, Gerdes J, O'Conner N, Wainscoat J, Pallesen G, Gatter K, Falini B, Delsol G, Lemke H, Schwarting R, Lennert K . The expression of the Hodgkin's-disease-associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Sternberg–Reed cells and histocytic malignancies are derived from activated lymphoid cells Blood 1985 66: 848–858 CASPubMed Google Scholar
Agnarsson BA, Kadin ME . The immunophenotype of Reed–Sternberg cells. A study of 50 cases of Hodgkin's lymphoma using fixed frozen tissue Cancer 1989 63: 2083–2087 ArticleCASPubMed Google Scholar
Kennedy IC, Hart DN, Colls BM . Nodular sclerosing, mixed cellularity and lymphocyte-depleted variants of Hodgkin's lymphoma are probable dendritic cell malignancies Clin Exp Immunol 1989 76: 324–331 CASPubMedPubMed Central Google Scholar
Delabie J, Ceuppens JL, Vandenberghe P, de Boer M, Coorevits L, de Wolf-Peeters C . The B7/BB1 antigen is expressed by Reed–Sternberg cells of Hodgkin's lymphoma and contributes to the stimulating capacity of Hodgkin's lymphoma-derived cell lines Blood 1993 82: 2845–2852 CASPubMed Google Scholar
Barth S, Schnell R, Diehl V, Engert A . Development of immunotoxins for potential clinical use in Hodgkin's disease Ann Oncol 1996 7: (Suppl. 4) 135–141 ArticlePubMed Google Scholar
Kreitman RJ, Pastan I . Recombinant single-chain immunotoxins against T and B cell leukemias Leuk Lymphoma 1994 13: 1–10 CASPubMed Google Scholar
Strauchen JA, Breakstone BA . IL-2 receptor expression in human lymphoid lesions. Immunohistochemical study of 166 cases Am J Pathol 1987 126: 506–512 CASPubMedPubMed Central Google Scholar
Engert A, Martin G, Amlot P, Wijdenes J, Diehl V, Thorpe P . Immunotoxins constructed with CD25 monoclonal antibodies and deglycosylated ricin A-chain have potent antitumor effects against human Hodgkin cells in vitro and solid Hodgkin tumors in mice Int J Cancer 1991 49: 450–456 ArticleCASPubMed Google Scholar
Winkler U, Gottstein C, Schön G, Kapp U, Wolf J, Hansmann ML, Bohlen H, Thorpe P, Diehl V, Engert A . Successful treatment of disseminated human Hodgkin's disease in SCID mice with deglycosylated ricin A-chain immunotoxins Blood 1994 83: 466–475 CASPubMed Google Scholar
Engert A, Diehl V, Schnell R, Radszuhn A, Hatwig MT, Drillich S, Schön G, Bohlen H, Tesch H, Hansmann ML, Barth S, Schindler J, Ghetie V, Uhr J, Vitetta E . A phase I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma Blood 1997 89: 403–410 CASPubMed Google Scholar
Thorpe PE, Wallace PM, Knowles PP, Relf MG, Browmn ANF, Watson GJ, Blakes DC, Newell DR . Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages Cancer Res 1988 48: 6396–6403 CASPubMed Google Scholar
Simon R . Optimal two-stage designs for phase II clinical trials Control Clin Trials 1989 10: 1–10 ArticleCASPubMed Google Scholar
Merz H, Malisius R, Mannweiler S, Zhou R, Hartmann W, Orscheschek K, Moubayed P, Feller AC . ImmunoMax. A maximized immunohistochemical method for the retrieval and enhancement of hidden antigens Lab Invest 1995 73: 149–156 CASPubMed Google Scholar
Sausville EA, Headlee D, Stetler-Stevenson M, Jaffe ES, Solomon D, Figg WD, Herdt J, Kopp WC, Rager H, Steinberg SM, Ghetie V, Schindler J, Uhr JW, Wittes RE, Vitetta ES . Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I study Blood 1995 85: 3457–3465 CASPubMed Google Scholar
Schumaker RC . A basic interactive complex program for statistical and pharmacokinetic analysis of data Drug Metab Rev 1986 17: 331–342 Article Google Scholar
Vitetta ES, Stone M, Amlot P, Fay J, May R, Till M, Newman J, Clark P, Collins R, Cunningham D, Ghetie V, Uhr J, Thorpe P . Phase-I immunotoxin trial in patients with B-cell lymphoma Cancer Res 1991 51: 4052–4058 CASPubMed Google Scholar
Amlot P, Stone MJ, Cunningham D, Fay J, Newman J, Collins R, May R, McCarthy M, Richardson J, Ghetie V, Ramillo O, Thorpe P, Uhr J, Vitetta ES . A phase I study of an anti-CD22-deglycosylated ricin A-chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy Blood 1993 82: 2624–2633 CASPubMed Google Scholar
Stone MJ, Sausville EA, Fay JW, Headlee D, Collins RH, Figg WD, Stetler-Stevenson M, Jain V, Jaffe ES, Solomon D, Lush RM, Senderowilz A, Ghetie V, Schindler J, Uhr JW, Vitetta ES . A phase I study of bolus vs. continuous infusion of the anti-CD19 immunotoxin, IgG-HL37-dgA in patients with B cell lymphoma Blood 1996 88: 1188–1197 CASPubMed Google Scholar
Maloney DG, Liles TM, Czerwinski DK, Waldichuk C, Rosenberg J, Grillo-Lopez A, Levy R . Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma Blood 1994 84: 2457–2466 CASPubMed Google Scholar
Mansfield E, Amlot P, Pastan I, FitzGerald DJ . Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors Blood 1997 90: 2020–2026 CASPubMed Google Scholar
Woodard SL, Fraser SA, Winkler U, Jackson DS, Kam CM, Powers JC, Hudig D . Purification and characterization of lymphocyte chymase I, a granzyme implicated in perforin-mediated lysis J Immunol 1998 160: 4988–4993 CASPubMed Google Scholar
Kreitman RJ, Chaudhary VK, Kozak RW, FitzGerald DJP, Waldmann TA, Pastan I . Recombinant toxins containing the variable domains of the anti-tac monoclonal antibody to the interleukin-2 receptor kill malignant cells from patients with chronic lymphocytic leukemia Blood 1992 80: 2344–2352 CASPubMed Google Scholar
Kreitman RJ, Chaudhary VK, Waldmann TA, Hanchard B, Cranston B, FitzGerald DJP, Pastan I . Cytotoxic activities of recombinant immunotoxins composed of Pseudomonas toxin or Diphtheria toxin toward lymphocytes from patients with adult T cell leukemia Leukemia 1993 7: 553–562 CASPubMed Google Scholar
Foss FM, Borkowski TA, Gilliom M, Stetler-Stevenson MA, Jaffe ES, Figg WD, Tompkins A, Bastian A, Nylen P, Woodworth T, Udey MC, Sausville EA . Chimeric fusion protein toxin DAB486IL-2 in advanced mycosis fungoides and the Sezary syndrome: correlation of activity and interleukin-2 receptor expression in a phase II study Blood 1994 84: 1765–1774 CASPubMed Google Scholar
LeMaistre CF, Mansoor NS, Kuzel TM, Foss F, Platanias LC, Schwarzt G, Ratain M, Rook A, Freytes CO, Craig F, Reuben J, Nichols JC . Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2 Blood 1998 91: 399–405 CASPubMed Google Scholar
Williams DP, Parker K, Bacha P, Bishai W, Borowski M, Genbauffe F, Strom TB, Murphy JR . Diphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein Prot Eng 1987 1: 493–498 ArticleCAS Google Scholar
LeMaistre CF, Craig FE, Meneghetti CM, McMullin B, Parker K, Reuben J, Boldt DH, Rosenblum M, Woodworth T . Phase-I trial of a 90-minute infusion of the fusion toxin DAB486IL-2 in hematological cancers Cancer Res 1993 53: 3930–3934 CASPubMed Google Scholar
LeMaistre CF, Meneghetti C, Rosenblum M, Reuben J, Parker K, Shaw J, Dieisseroth A, Woodworth T, Parkinson DR . Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptor Blood 1992 79: 2547–2554 CASPubMed Google Scholar
Tepler I, Schwartz G, Parker K, Charette J, Kadin ME, Woodworth TG, Schnipper LE . Phase-I trial of an interleukin-2 fusion toxin (DAB486IL-2) in hematologic malignancies: complete response in a patient with Hodgkin's disease refractory to chemotherapy Cancer 1994 73: 1276–1285 ArticleCASPubMed Google Scholar
Tazzari PL, Bolognesi A, de Totero D, Falini B, Lemoli RM, Soria MR, Pileri S, Gobbi M, Stein H, Flenghi L, Martelli MF, Stirpe F . Ber-H2 (anti-CD30)-saporin immunotoxin: a new tool for the treatment of Hodgkin's lymphoma and CD30+ lymphoma: in vitro evaluation Br J Haematol 1992 81: 203–211 ArticleCASPubMed Google Scholar
Falini B, Bolognesi A, Flenghi L, Tazzari PL, Broe MK, Stein H, Dürkopp H . Response of refractory Hodgkin's lymphoma to monoclonal anti-CD30 immunotoxin Lancet 1992 339: 1195–1196 ArticleCASPubMed Google Scholar
Falini B, Pasqualucci L, Flenghi L, Bologneri A, Kadin M, Stein H, Martinelli MF, Stirpe F . Anti-CD30 immunotoxins: experimental and clinical studies Abstracts of the Fourth International Symposium on Immunotoxins 1995 160A
Engert A, Burrows F, Jung W, Tazzari PL, Stein H, Pfreundschuh M, Diehl V, Thorpe P . Evaluation of ricin A-chain-containing immunotoxins directed against the CD30 antigen as potential reagents for the treatment of Hodgkin's lymphoma Cancer Res 1990 50: 84–88 CASPubMed Google Scholar
Horn-Lohrens O, Tiemann M, Lange H, Kobarg J, Hafner M, Hansen H, Sterry W, Parwaresch RM, Lemke H . Shedding of the soluble form of CD30 from the Hodgkin-analogous cell line L540 is strongly inhibited by a new CD30-specific antibody (Ki-4) Int J Cancer 1995 60: 539–544 ArticleCASPubMed Google Scholar
Schnell R, Linnartz C, Schön G, Katouzi A, Bohlen H, Horn-Lohrens O, Parwaresch R, Diehl V, Lemke H, Engert A . Development of new ricin A-chain immunotoxins with potent anti-tumor effects against human Hodgkin cells in vitro and disseminated Hodgkin tumors in SCID mice using high-affinity monoclonal antibodies directed against the CD30 antigen Int J Cancer 1995 63: 238–244 ArticleCASPubMed Google Scholar
Engert A, Gottstein C, Bohlen H, Winkler U, Schön G, Manske O, Schnell R, Diehl V, Thorpe P . Cocktails of ricin A-chain immunotoxins against different antigens of Hodgkin and Sternberg–Reed cells have superior anti-tumor effects against H-RS cells in vitro and solid Hodgkin tumors in mice Int J Cancer 1995 63: 304–309 ArticleCASPubMed Google Scholar
Katz FE, Janossy G, Cumber A, Ross W, Blacklock HA, Tax W, Thorpe PE . Elimination of T cells from human peripheral blood and bone marrow using a cocktail of three anti-T cell immunotoxins Br J Haematol 1987 67: 407–411 ArticleCASPubMed Google Scholar
Ghetie MA, Tucker K, Richardson J, Uhr JW, Vitetta ES . The antitumor activity of an anti-CD 22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin Blood 1992 80: 2315–2320 CASPubMed Google Scholar
Hartmann F, Renner C, Jung W, Deisting C, Juwana M, Eichentopf B, Kloft M, Pfreundschuh M . Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody Blood 1997 89: 2042–2047 CASPubMed Google Scholar
Barth S, Engert A . Recombinant immunotoxins for the treatment of Hodgkin's lymphoma Leuk Lymphoma 1998 29: (Suppl. 1) O–10 Google Scholar
Klimka A, Roovers RC, Barth S, Bot F, Engert A, Arends JW, Hoogenboom HR . Human anti-CD30 phage antibody by guided selection for imunotherapy of Hodgkin's lymphoma Leuk Lymphoma 1998 29: (Suppl. 1) P–112 Google Scholar